Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with ...
Tag: Guselkumab
Promising phase 2 results for new plaque psoriasis therapy
1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha ...
